HIV/AIDS. Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases
Conditions
Interventions
Intervention 1: Intervention group: In this clinical trial, after getting consent of participants, we will conduct interviews based on questionnaires and following by that body composition of particip
Intervention group: In this clinical trial, after getting consent of participants, we will conduct interviews based on questionnaires and following by that body composition of participants will be mea
Control group: In this group no intervention will be made.
Sponsors
Resaerch Deputy of Tehran University of Medical Sciences
Eligibility
Sex/Gender
Male
Age
18 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Be between 18 to 45 years old; don’t be on highly active antiretroviral therapy or do not take any antiretroviral treatment at least in last six months; do not be actively addicted to any drug; be cooperative in this study and follow ups; do not have physical exercises in last six months. Exclusion criteria: Takes psychological drugs; has unstable condition regarding HIV infection status; has exacerbation in health condition during the study in a way that he could not do physical exercises
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD4 level. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Laboratory tests. | — |
Secondary
| Measure | Time frame |
|---|---|
| Sleep quality. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Sleep Quality questionnaire (PSQI).;Anxiety and depression. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Anxiety and Depression questionnaire (HAD).;Body composition. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Body composition device.;Quality of life. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Quality of life questionnaire (SF-36).;Clinical symptoms. Timepoint: Before intervention and 4 months after intervention. Method of measurement: Clinical symptoms checklist (MSCL & SCL90-R). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Minoo Mohraz
Iranian Research Center for HIV/AIDS (IRCHA)
Outcome results
None listed